Piramal Pharma Solutions supports George Medicines in developing new drug for hypertension

image credit- shutterstock

London-based George Medicines, a leading late-stage biopharma company, in partnership with Mumbai-based Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., has developed WIDAPLIK, a new drug for treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure. The US Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025.

WIDAPLIK is a single pill combination of three medicines, telmisartan, amlodipine, and indapamide, for the treatment of hypertension, developed in three doses (10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg strengths), including two doses that are lower than those currently available in single pill combinations.

It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the established safety profile of its three component antihypertensive medications.

George Medicines and Piramal Pharma Solutions began their collaboration on WIDAPLIK in December 2018, when the formulation was developed at Piramal's Pharmaceutical Development site in Ahmedabad. In June 2020, the project was transferred to Piramal's drug product facility in Pithampur for validation and manufacturing. Leveraging Piramal's vast technical expertise and extensive experience advancing innovations, George Medicines achieved FDA approval for WIDAPLIK this year.